The estimated Net Worth of Nora Brennan is at least $1.54 millió dollars as of 26 May 2023. Ms. Brennan owns over 32,387 units of TELA Bio stock worth over $1,499,066 and over the last 5 years she sold TELA stock worth over $38,445. In addition, she makes $0 as Chief Financial Officer at TELA Bio.
Nora has made over 2 trades of the TELA Bio stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 32,387 units of TELA stock worth $35,626 on 26 May 2023.
The largest trade she's ever made was selling 32,387 units of TELA Bio stock on 26 May 2023 worth over $35,626. On average, Nora trades about 3,995 units every 38 days since 2019. As of 26 May 2023 she still owns at least 567,828 units of TELA Bio stock.
You can see the complete history of Ms. Brennan stock trades at the bottom of the page.
Nora Brennan serves as Chief Financial Officer of the Company. Nora Brennan has served as our Chief Financial Officer since January 2019. Previously, Ms. Brennan performed consulting services from April 2018 until January 2019 and served as Chief Financial Officer at Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, from June 2017 until April 2018. From 2006 to June 2017, she was employed at Integra Lifesciences Corporation, a global medical device company, where she held various senior leadership roles, including Senior Vice President, Investor Relations and Corporate Treasurer. Prior to joining Integra, Ms. Brennan worked at Citigroup and JP Morgan in various finance and investment banking roles. Ms. Brennan holds a Master of Business Administration degree from the University of Chicago Booth School of Business and a Bachelor of Arts from the University of Illinois.
Nora Brennan is 51, she's been the Chief Financial Officer of TELA Bio since 2019. There are 12 older and 2 younger executives at TELA Bio. The oldest executive at TELA Bio, Inc. is Maarten Persenaire, 63, who is the Co-Founder, Chief Medical Officer.
Nora's mailing address filed with the SEC is 2 ATLANTIC AVENUE, , BOSTON, MA, 02110.
Over the last 5 years, insiders at TELA Bio have traded over $4,222,376 worth of TELA Bio stock and bought 4,343,227 units worth $46,898,981 . The most active insiders traders include Management Inc. Opaleye, Investments, Lpwong Roderic... és Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of $139,070. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth $2,021,576.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Bio executives and other stock owners filed with the SEC include: